Elevated levels of serum interleukin-6 (IL-6) are a hallmark inflammatory signature commonly seen in patients with severe COVID-19 and the use of IL-6-receptor blocking antibodies has recently been approved in China for treatment of COVID-19 patients with serious pulmonary damage and elevated serum IL-6 levels (3). This evidence concerns the gene IL6 and COVID-19.